MaxCyte Signs Strategic Platform License with Curamys to Enable Cell and Gene Therapies
December 5, 2022
Cell engineering company MaxCyte said it entered into a strategic platform license agreement with South Korea-based Curamys.
Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Curamys is focused on developing treatments for genetic and degenerative diseases through its specialized cell fusion technology, based on the concept that apoptotic or dying cells can be regenerated by fusing them with healthy normal cells. Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of a treatments for genetic and rare intractable diseases at the cellular level.
“At Curamys, our goal is to use cell fusion-based technologies to transform the biomedical sciences by helping to identify genetic factors contributing to numerous rare diseases with unknown medical causes,” said Jung Joon Sung, CEO of Curamys. “MaxCyte’s Platform will enable us to advance this technology so we can expand our global reach and ultimately, help more patients living with rare diseases.”
By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Curamys is MaxCyte’s 18th SPL overall, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.
“A recent report estimates that there are more than 10,000 distinct rare diseases affecting 400 million people around the world,” said Doug Doerfler, president and CEO of MaxCyte. “Many of these diseases, like ALS and DMD, have few or no treatments.”
Author: Rare Daily Staff
Sign up for updates straight to your inbox.